SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending due to a Cornell University study highlighting its APU's comparable performance to NVIDIA GPUs with significantly lower energy consumption, sparking community interest in potential buyouts and market disruption within the AI space. Community members are actively discussing the implications for the AI market and potential competition with major players, while some speculate on possible acquisitions. The stock's surge is also attracting attention from traders looking for the next big move in the AI and semiconductor sectors.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the community debates recent price action and potential market manipulation, with some expressing frustration over its inability to sustain gains. Discussions include speculation on upcoming catalysts and technical analysis, while others point to concerns over the influence of large investment firms. Overall, sentiment seems mixed with a focus on identifying the next key price levels.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending due to its strategic shift towards high-performance computing (HPC) and AI infrastructure, highlighted by a partnership with Bell Canada to build a sovereign AI ecosystem. The community is discussing analyst ratings boosts and expansion into renewable-powered data centers, viewing HIVE as more than just a Bitcoin miner. This transition diversifies HIVE's revenue streams and positions it to capitalize on the growing demand for AI and HPC solutions.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as community members discuss the potential impact of upcoming catalysts, including a CMS rule update, real-world data releases, and potential TDAPA legislation; the company's recent earnings and revenue guidance are also sparking debate around future growth and valuation. Community members are focused on Rezzayo data and its efficacy against deadly fungus, as well as potential financial outcomes based on analyst estimates.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending due to positive clinical data from a partner's lung cancer drug trial in China, demonstrating promising response rates. The community is actively discussing the implications of these results, comparing them to competitors and speculating on potential short squeezes. Despite optimism, concerns about cash position, past volatility, and management's history temper enthusiasm among some investors.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies Group is trending due to optimism surrounding its potential for profitability by the end of 2024, driven by rising earnings and recurring revenue. Community members are discussing the company's undervalued status and its strategic positioning in the data center infrastructure and gas turbine sectors, which are experiencing significant demand. Investors believe the company's story is not well-known, and that upcoming financial results could be a catalyst for substantial gains.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a failed phase 3 trial for its anxiety drug, though discussions highlight its partnership with Merck for an Alzheimer's drug and a cash runway extending to Q2 2027. Despite the trial setback, some traders believe the stock is oversold, presenting a short-term buying opportunity, while others are concerned about the company's cash position and pipeline.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF (BTC) is trending as the broader crypto market experiences volatility, prompting discussions about potential bear market conditions and strategic investment approaches. Community members are actively analyzing market trends, debating the merits of spot trading versus futures, and identifying potential moonshot opportunities in Solana-based tokens. Some traders are expressing concerns about market manipulation and the influence of major players on Bitcoin's price.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos ($XTZ) is trending amidst discussions about potential market movements and the impact of macroeconomic factors like FED rate cuts. Community members are debating whether to hold or sell, with some expressing concerns about its potential while others anticipate a bullish altcoin season. The conversation includes speculation about potential price targets and frustration with the token's performance.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors await key updates on its pipeline, particularly CAN-3110 data, while also weighing the implications of recent non-dilutive financing. Discussions center on potential partnerships, the company's financial positioning, and the long-term prospects for its cancer therapies. Bullish community members express confidence in upcoming catalysts and Candel's potential within the broader biotech sector.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges

NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1...

NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data

NuCana will discontinue the NuTide:323 study after an initial analysis recommended by the Steering Committee, as the combination treatment was unlikely to achieve superior Progression-Free Survival...

NuCana plc (NASDAQ:NCNA) Sees Significant Growth in Short Interest

NuCana plc (NASDAQ:NCNA  Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,480,000...

Why NuCana (NCNA) Shares Are Trading Lower

NuCana shares are trading lower by 16.6% during Thursday's session. The company late Wednesday said it intends to adjust the ratio of its American Depository Shares (ADSs).
read more...

Truist Financial Sticks to Its Buy Rating for Nucana (NCNA)

In a report released today, Robyn Karnauskas from Truist Financial maintained a Buy rating on Nucana (NCNA Research Report). The company's shares...

NuCana Announces Plan to Implement ADS Ratio Change

EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares ( ADSs ) to its ordinary shares from...

Short Interest in NuCana plc (NASDAQ:NCNA) Expands By 2,616.3%

William Blair Comments on NuCana plc's FY2024 Earnings (NASDAQ:NCNA)

NuCana plc (NASDAQ:NCNA  Free Report)  Stock analysts at William Blair issued their FY2024 EPS estimates for NuCana in a research note issued to investors on Thursday, March 21st...

NuCana GAAP EPS of -?0.14

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Pipeline Continues to Advance with Key Data Readouts Expected for All Programs in 2024...

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

NCNA
NuCana plc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NCNA News

NCNANuCana plc